PerkinElmer Selected by the State of California to Supply Solutions for Expanded Newborn Screening
PerkinElmer Inc. (NYSE: PKI), the world’s leading provider of neonatal screening systems, and a leading provider of drug discovery, life science research, and analytical solutions, today announced that it has signed long-term agreements with the state of California to supply Tandem Mass Spectrometry systems in support of the state’s expanded newborn screening program.
PerkinElmer’s NeoGram Amino Acids and Acylcarnitines Kit recently became the world’s first multi-analyte kit cleared by the FDA for newborn metabolic screening using Tandem Mass Spectrometry. Subsequent to validation of requested enhancements, PerkinElmer will provide California’s contracted newborn screening laboratories with tandem mass spectrometry systems, reagent kits and software. In addition, a system will be placed in California’s Genetic Disease Laboratory (GDL) located in Richmond, California, where trained scientists will oversee and analyze all of the results from the screening labs, and perform quality control oversight.
PerkinElmer will also provide California’s contracted newborn screening laboratories with 17-OHP assay kits, which allows for the screening of congenital adrenal hyperplasia (CAH). CAH can be fatal if left undetected. PerkinElmer anticipates that this system will be available for sale in late 2004 or early 2005.
“We are pleased to continue to support the state of California in its effort to develop a state-of-the-art newborn screening program,” said Gregory L. Summe, PerkinElmer Chairman and Chief Executive Officer. “By utilizing PerkinElmer’s leading-edge technology, an early detection program allows for treatment and management options for a range of diseases, leading to an improved quality of life.”
PerkinElmer is the world’s leading supplier to newborn screening laboratories. Every baby screened in the United States today is tested with one of PerkinElmer’s many products.
Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that relate to prospective events or developments, including, without limitation, all projections of future financial results and plans concerning business development opportunities, are deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions are intended to identify forward-looking statements. There are a number of important risk factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including, without limitation, economic and geopolitical forces that may limit any continued or expected economic or end market strengthening or recoveries, risks related to our failure to introduce new products in a timely manner, the impact of our debt on our cash flow and investment opportunities, our ability to comply with financial covenants contained in our credit agreements and debt instruments, cyclical downturns continuing to affect several of the industries into which we sell our products, our ability to adjust our operations to address unexpected changes, our ability to execute acquisitions and license technologies and successfully integrate acquired businesses and licensed technologies into our existing business, the loss of any of our licenses that may require us to stop selling products or lose competitive advantage, competition, regulatory compliance, regulatory changes, our failure to obtain and enforce intellectual property protection, our defense of third party claims of patent infringement and our ability to realize the full value of our intangible assets, as well as other factors which we describe under the caption “Forward-Looking Information and Factors Affecting Future Performance” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q, each on file with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
PerkinElmer, Inc. is a global technology leader focused in the following businesses – Life and Analytical Sciences, Optoelectronics and Fluid Sciences. Combining operational excellence and technology expertise with an intimate understanding of our customers’ needs, PerkinElmer provides products and services in health sciences and other advanced technology markets that require innovation, precision and reliability. The Company serves customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.
